Stempeutics Research Private Limited

Stempeutics is a leading Regenerative Medicine company in Bangalore with our patented stem-cell therapy platform technology developing treatment of cardiovascular, immune-mediated and degenerative diseases. The companys flagship product, Stempeucel has received market authorization to treat Critical Limb Ischemia a major unmet medical need in India. It is the FIRST innovative cell therapy based product to get marketing approval in India and Globally. CIPLA, the Indian licensee, has commenced pan-India commercialization. It has the FIRST DCGI approved Cell therapy product for Knee Osteoarthritis being marketed by Alkem. Stempeutics has a product in the Phase 3 stage covering Diabetic Foot Ulcer. Further it is conducting Phase 2 trial in Perianal fistula due to Crohns disease. Stempeucel has strong patent protection with 20 patents granted including US, Europe and Japan. Stempeucel has been classified as an Advanced Therapy Medicinal Product (ATMP) and designated as an Orphan Drug...